Leaderboards/Heart Failure Treatment and Management

Heart Failure Treatment and Management

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Th. McDonagh
King's College Hospital
2
Jun Ran
Chinese Academy of Medical Sciences & Peking Union Medical College
3
Jishnu Malgie
Erasmus MC
4
Safia Chatur
Brigham and Women's Hospital
5
Job J. Herrmann
Radboud University Nijmegen
6
Bart J. van Essen
University Medical Center Groningen
7
Stephen Fahy
Charité - Universitätsmedizin Berlin
8
Karola Jering
Brigham and Women's Hospital
9
Misato Chimura
British Heart Foundation
10
Gavin A. Lewis
University of Liverpool

Papers

1
Publication in Biomarker Research (2025) [96 citations, W4406767289]
Biomarker Research|2025
96 cit.
2
Publication in Journal of Personalized Medicine (2024) [60 citations, W4390972832]
Journal of Personalized Medicine|2024
60 cit.
3
Publication in European Journal of Heart Failure (2024) [56 citations, W4396845721]
European Journal of Heart Failure|2024
56 cit.
4
Publication in European Heart Journal (2024) [47 citations, W4405912176]
European Heart Journal|2024
47 cit.
5
Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
Journal of the American College of Cardiology|2024
25 cit.
6
Publication in Journal of Personalized Medicine (2024) [25 citations, W4396745459]
Journal of Personalized Medicine|2024
25 cit.
7
Publication in European Heart Journal (2025) [25 citations, W4409735883]
European Heart Journal|2025
25 cit.
8
Publication in Circulation Heart Failure (2024) [21 citations, W4402958506]
Circulation Heart Failure|2024
21 cit.
9
Publication in JAMA Cardiology (2024) [21 citations, W4404449447]
JAMA Cardiology|2024
21 cit.
10
Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial
Nature Medicine|2025
17 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Anne Kathrine Skibelund
World Economic Forum
2
Quentin R. Youmans
Northwestern University
3
Christopher E. Kurtz
San Francisco VA Medical Center
4
Cory R. Trankle
Virginia Commonwealth University
5
Y. Joseph Woo
Unknown
6
Sadiya S. Khan
Northwestern University
7
Alexander R Lyon
Royal Brompton Hospital
8
Danielle Enserro
NRG Oncology
9
Mari Carmen Moreno García
Universitat de Vic - Universitat Central de Catalunya
10
Brenda Moura
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Papers

1
Development and Validation of the American Heart Association’s PREVENT Equations
Circulation|2023
929 cit.
2
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure
Journal of Cardiac Failure|2022
406 cit.
3
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC
Revista Española de Cardiología (English Edition)|2022
297 cit.
4
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
Journal of the American College of Cardiology|2024
256 cit.
5
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
Revista Española de Cardiología|2022
123 cit.
6
Trends in the Incidence of New‐Onset Hypertensive Disorders of Pregnancy Among Rural and Urban Areas in the United States, 2007 to 2019
Journal of the American Heart Association|2022
118 cit.
7
Coronary Artery Calcium Score and Polygenic Risk Score for the Prediction of Coronary Heart Disease Events
JAMA|2023
106 cit.
8
Rural–Urban Disparities in Adverse Maternal Outcomes in the United States, 2016–2019
American Journal of Public Health|2023
76 cit.
9
Temporal Trends in Adverse Pregnancy Outcomes in Birthing Individuals Aged 15 to 44 Years in the United States, 2007 to 2019
Journal of the American Heart Association|2022
70 cit.
10
Associations of Clinical and Social Risk Factors With Racial Differences in Premature Cardiovascular Disease
Circulation|2022
70 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Bruce L. Wilkoff
Cleveland Clinic
2
Harlan M. Krumholz
Yale New Haven Hospital
3
Gregg C. Fonarow
UCLA Medical Center
4
John J.V. McMurray
University of Glasgow
5
Jay N. Cohn
University of Minnesota
6
John C. Burnett
Mayo Clinic in Arizona
7
Clyde W. Yancy
Northwestern Memorial Hospital
8
Adriaan A. Voors
University Medical Center Groningen
9
Scott D. Solomon
Brigham and Women's Hospital
10
Salim Yusuf
Population Health Research Institute

Papers

1
2013 ACCF/AHA Guideline for the Management of Heart Failure
Journal of the American College of Cardiology|2013
12.6k cit.
2
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
The Lancet|2004
12k cit.
3
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
New England Journal of Medicine|2019
6.9k cit.
4
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
New England Journal of Medicine|2014
6.8k cit.
5
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study
The Lancet|2010
3.5k cit.
6
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Journal of the American College of Cardiology|2017
3.4k cit.
7
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Circulation|2013
3.3k cit.
8
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Progress in Cardiovascular Diseases|1985
3.2k cit.
9
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
New England Journal of Medicine|1984
3.1k cit.
10
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
New England Journal of Medicine|2001
3.1k cit.

Reagents for Heart Failure Treatment and Management

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 67

MGMT Antibody

#2739$317
View Evidence →
Cell Signaling TechnologyEvidence 66

NSF Antibody

#2145$317
View Evidence →
Cell Signaling TechnologyEvidence 64

Bcl-2 (124) Mouse Monoclonal Antibody (BSA and Azide Free)

#17447$865
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 67

Vimentin (D21H3) Rabbit Monoclonal Antibody (APC Conjugate)

Cited in 5 papers
#95159$465
View Evidence →
Cell Signaling Technology

PATL1/PAT1b (D8P1B) Rabbit Monoclonal Antibody

Cited in 5 papers
#14288$161,351
View Evidence →
Cell Signaling TechnologyEvidence 68

Synapsin Antibody

Cited in 5 papers
#2312$317
View Evidence →